Table 1.
Patient characteristics [8]
| Trial | INHANCE | INLIGHT-2 |
|---|---|---|
| Study arms |
Indacaterol 150 μg Indacaterol 300 μg Tiotropium 18 μg |
Indacaterol 150 μg Salmeterol 2 × 50 μg |
| Length of study | 26 weeks | 26 weeks |
| Number of subjects (randomised) | 1683 | 998 |
| Mean age, years (standard deviation) | 63.6 (9.1) | 63.5 (8.81) |
| Proportion of males (%) | 62.8 | 74.6 |
| Duration of COPD, years (standard deviation) | 6.8 (6.75) | 6.5 (5.71) |
| Starting disease severity distribution (%) | ||
| Mild COPD | 1.4 | 1.2 |
| Moderate COPD | 36.7 | 41.3 |
| Severe COPD | 50.2 | 49.4 |
| Very Severe COPD | 11.69 | 8.1 |